The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jul 2, 2026 | Muhsin Bilal | EVP & President Connected Care | Tax withholding(F) | 2K | — | $0 |
| Jul 1, 2026 | Muhsin Bilal | EVP & President Connected Care | Grant(A) | 14K | — | $0 |
| Jun 26, 2026 | Feld Michael | EVP, Chief Revenue Officer | Sell(S) | 75 | $152.80 | $11K |
| Jun 24, 2026 | Garrison Michael David | EVP & Pres Med.Essntl&BioPharm | Sell(S) | 1K | $145.66 | $160K |
| Jun 10, 2026 | Garrison Michael David | EVP & Pres Med.Essntl&BioPharm | Sell(S) | 1K | $151.48 | $167K |
| Jun 1, 2026 | Polen Thomas E Jr | Chairman, CEO and President, Director | Option exercise(M) | 20K | $126.16 | $2.5M |
| Jun 1, 2026 | Polen Thomas E Jr | Chairman, CEO and President, Director | Disposed to issuer(D) | 17K | $146.15 | $2.5M |
| Jun 1, 2026 | Polen Thomas E Jr | Chairman, CEO and President, Director | Sell(S) | 3K | $146.35 | $405K |
| Jun 1, 2026 | Polen Thomas E Jr | Chairman, CEO and President, Director | Option exercise(M) | 20K | — | $0 |
| Jun 1, 2026 | Menziuso Peter | EVP and President, BDI | Grant(A) | 14K | — | $0 |
| May 26, 2026 | Feld Michael | EVP, Chief Revenue Officer | Sell(S) | 75 | $147.35 | $11K |
| May 8, 2026 | Byington Carrie L | Director | Grant(A) | 105 | $149.04 | $16K |
| May 8, 2026 | Huffines Robert Luther | Director | Grant(A) | 210 | $149.04 | $31K |
| May 7, 2026 | Roque Vitor | EVP & Chief Financial Officer | Grant(A) | 2K | — | $0 |
| Apr 27, 2026 | Feld Michael | EVP, Chief Revenue Officer | Sell(S) | 74 | $151.94 | $11K |
| Apr 6, 2026 | Neal Shana Carol | EVP and Chief People Officer | Tax withholding(F) | 1K | — | $0 |
| Mar 26, 2026 | Feld Michael | EVP, Chief Revenue Officer | Sell(S) | 75 | $156.83 | $12K |
| Mar 16, 2026 | Minnix Lanesha | EVP and General Counsel | Grant(A) | 7K | — | $0 |
| Mar 2, 2026 | Spikner Pamela L. | SVP Controller & CAO | Grant(A) | 931 | — | $0 |
| Mar 2, 2026 | Roque Vitor | Interim CFO | Grant(A) | 931 | — | $0 |
| Feb 26, 2026 | Feld Michael | EVP, Chief Revenue Officer | Sell(S) | 75 | $181.84 | $14K |
| Feb 18, 2026 | Scott Bertram L | Director | Sell(S) | 953 | $182.61 | $174K |
| Feb 4, 2026 | Jones Christopher Ian Montague | Director | Grant(A) | 272 | $201.91 | $55K |
| Feb 4, 2026 | Byington Carrie L | Director | Grant(A) | 30 | $201.91 | $6K |
| Feb 4, 2026 | Huffines Robert Luther | Director | Grant(A) | 100 | $201.91 | $20K |
| Jan 27, 2026 | Wright Jacqueline | Director | Grant(A) | 1K | — | $0 |
| Jan 27, 2026 | Waldstreicher Joanne | Director | Grant(A) | 1K | — | $0 |
| Jan 27, 2026 | Scott Bertram L | Director | Grant(A) | 1K | — | $0 |
| Jan 27, 2026 | Ring Timothy M | Director | Grant(A) | 1K | — | $0 |
| Jan 27, 2026 | Jones Christopher Ian Montague | Director | Grant(A) | 1K | — | $0 |
| Jan 27, 2026 | Huffines Robert Luther | Director | Grant(A) | 1K | — | $0 |
| Jan 27, 2026 | Brown William M | Director | Grant(A) | 1K | — | $0 |
| Jan 27, 2026 | Hayes Gregory | Director | Grant(A) | 1K | — | $0 |
| Jan 27, 2026 | Byington Carrie L | Director | Grant(A) | 1K | — | $0 |
| Jan 27, 2026 | Eckert R Andrew | Director | Grant(A) | 1K | — | $0 |
| Jan 27, 2026 | Henderson Jeffrey William | Director | Grant(A) | 1K | — | $0 |
| Jan 26, 2026 | Feld Michael | EVP, CRO & Pres. Life Sciences | Sell(S) | 75 | $202.73 | $15K |
| Jan 21, 2026 | Spikner Pamela L. | SVP Controller & CAO | Tax withholding(F) | 84 | — | $0 |
| Jan 15, 2026 | Garrison Michael David | EVP & Pres Med.Essntl&BioPharm | Sell(S) | 1K | $206.54 | $209K |
| Jan 15, 2026 | Garrison Michael David | EVP & Pres Med.Essntl&BioPharm | Sell(S) | 600 | $209.00 | $125K |
| Jan 15, 2026 | Garrison Michael David | EVP & Pres Med.Essntl&BioPharm | Option exercise(M) | 3K | $167.91 | $513K |
| Jan 15, 2026 | Garrison Michael David | EVP & Pres Med.Essntl&BioPharm | Disposed to issuer(D) | 2K | $209.00 | $513K |
| Jan 15, 2026 | Garrison Michael David | EVP & Pres Med.Essntl&BioPharm | Option exercise(M) | 3K | — | $0 |
| Jan 3, 2026 | Shan David | EVP and Chief ISC Officer | Tax withholding(F) | 44 | — | $0 |
| Dec 26, 2025 | Feld Michael | EVP, CRO & Pres. Life Sciences | Sell(S) | 74 | $196.08 | $15K |
| Dec 17, 2025 | Garrison Michael David | EVP & Pres Med.Essntl&BioPharm | Sell(S) | 629 | $196.03 | $123K |
| Dec 1, 2025 | Huffines Robert Luther | Director | Grant(A) | 180 | — | $0 |
| Dec 1, 2025 | Wright Jacqueline | Director | Grant(A) | 180 | — | $0 |
| Dec 1, 2025 | Feld Michael | EVP, CRO & Pres. Life Sciences | Sell(S) | 75 | $193.36 | $15K |
| Nov 26, 2025 | Spikner Pamela L. | SVPController & Chief Acct Off | Grant(A) | 1K | — | $0 |
| Nov 26, 2025 | Polen Thomas E Jr | Chairman, CEO and President | Grant(A) | 23K | — | $0 |
| Nov 26, 2025 | Polen Thomas E Jr | Chairman, CEO and President | Tax withholding(F) | 17K | — | $0 |
| Nov 26, 2025 | Polen Thomas E Jr | Chairman, CEO and President | Grant(A) | 166K | — | $0 |
| Nov 26, 2025 | Muhsin Bilal | EVP & President Connected Care | Grant(A) | 10K | — | $0 |
| Nov 26, 2025 | Byrd Richard | EVP & President Interventional | Tax withholding(F) | 2K | — | $0 |
| Nov 26, 2025 | Byrd Richard | EVP & President Interventional | Grant(A) | 2K | — | $0 |
| Nov 26, 2025 | Byrd Richard | EVP & President Interventional | Grant(A) | 6K | — | $0 |
| Nov 26, 2025 | DelOrefice Christopher | EVP & Chief Financial Officer | Tax withholding(F) | 4K | — | $0 |
| Nov 26, 2025 | DelOrefice Christopher | EVP & Chief Financial Officer | Grant(A) | 6K | — | $0 |
| Nov 26, 2025 | Feld Michael | EVP, CRO & Pres. Life Sciences | Grant(A) | 9K | — | $0 |
| Nov 26, 2025 | Feld Michael | EVP, CRO & Pres. Life Sciences | Tax withholding(F) | 419 | — | $0 |
| Nov 26, 2025 | Garrison Michael David | EVP & Pres Med.Essntl&BioPharm | Tax withholding(F) | 2K | — | $0 |
| Nov 26, 2025 | Garrison Michael David | EVP & Pres Med.Essntl&BioPharm | Grant(A) | 3K | — | $0 |
| Nov 26, 2025 | Garrison Michael David | EVP & Pres Med.Essntl&BioPharm | Grant(A) | 8K | — | $0 |
| Nov 26, 2025 | Goette Roland | EVP and President, EMEA | Grant(A) | 1K | — | $0 |
| Nov 26, 2025 | Goette Roland | EVP and President, EMEA | Tax withholding(F) | 138 | — | $0 |
| Nov 26, 2025 | Goette Roland | EVP and President, EMEA | Grant(A) | 2K | — | $0 |
| Nov 26, 2025 | Neal Shana Carol | EVP and Chief People Officer | Grant(A) | 4K | — | $0 |
| Nov 26, 2025 | Neal Shana Carol | EVP and Chief People Officer | Grant(A) | 7K | — | $0 |
| Nov 26, 2025 | Neal Shana Carol | EVP and Chief People Officer | Tax withholding(F) | 2K | — | $0 |
| Nov 26, 2025 | Shan David | EVP and Chief ISC Officer | Grant(A) | 1K | — | $0 |
| Nov 26, 2025 | Shan David | EVP and Chief ISC Officer | Grant(A) | 4K | — | $0 |
| Nov 26, 2025 | Shan David | EVP and Chief ISC Officer | Tax withholding(F) | 134 | — | $0 |
| Nov 26, 2025 | Mocherla Pavan Kumar | EVP & President, Greater Asia | Grant(A) | 708 | — | $0 |
| Nov 26, 2025 | Mocherla Pavan Kumar | EVP & President, Greater Asia | Grant(A) | 2K | — | $0 |
| Nov 7, 2025 | Scott Bertram L | Director | Sell(S) | 217 | $176.58 | $38K |
| Nov 4, 2025 | Jones Christopher Ian Montague | Director | Grant(A) | 168 | $178.71 | $30K |
| Nov 4, 2025 | Byington Carrie L | Director | Grant(A) | 34 | $178.71 | $6K |
| Oct 27, 2025 | Feld Michael | EVP & President, Life Sciences | Sell(S) | 57 | $186.01 | $11K |
| Sep 26, 2025 | Feld Michael | EVP & President, Life Sciences | Sell(S) | 58 | $181.03 | $10K |
| Sep 10, 2025 | Fraser Claire | Director | Sell(S) | 917 | $187.50 | $172K |
| Sep 1, 2025 | Byrd Richard | EVP & President Interventional | Tax withholding(F) | 216 | — | $0 |
| Sep 1, 2025 | DelOrefice Christopher | EVP & Chief Financial Officer | Tax withholding(F) | 278 | — | $0 |
| Aug 22, 2025 | Feld Michael | EVP & President, Life Sciences | Sell(S) | 57 | $197.99 | $11K |
| Aug 20, 2025 | Feld Michael | EVP & President, Life Sciences | Tax withholding(F) | 773 | — | $0 |
| Aug 11, 2025 | Hayes Gregory | Director | Buy(P) | 5K | $191.57 | $1.0M |
| Aug 8, 2025 | Fraser Claire | Director | Sell(S) | 863 | $192.30 | $166K |
| Aug 7, 2025 | Byington Carrie L | Director | Grant(A) | 34 | $178.25 | $6K |
| Aug 7, 2025 | Jones Christopher Ian Montague | Director | Grant(A) | 168 | $178.25 | $30K |
| Jul 18, 2025 | Garrison Michael David | EVP & President, Medical | Option exercise(M) | 6K | $147.68 | $939K |
| Jul 18, 2025 | Garrison Michael David | EVP & President, Medical | Disposed to issuer(D) | 5K | $180.29 | $933K |
| Jul 18, 2025 | Garrison Michael David | EVP & President, Medical | Sell(S) | 1K | $180.29 | $213K |
| Jul 18, 2025 | Garrison Michael David | EVP & President, Medical | Sell(S) | 1 | $181.50 | $182 |
| Jul 18, 2025 | Garrison Michael David | EVP & President, Medical | Option exercise(M) | 6K | — | $0 |
| Jul 2, 2025 | Muhsin Bilal | EVP & President Connected Care | Grant(A) | 12K | — | $0 |
| Jun 2, 2025 | Shan David | EVP and Chief ISC Officer | Sell(S) | 1K | $171.19 | $200K |
| May 6, 2025 | Byington Carrie L | Director | Grant(A) | 29 | $207.09 | $6K |
| May 6, 2025 | Jones Christopher Ian Montague | Director | Grant(A) | 145 | $207.09 | $30K |
| Apr 9, 2025 | Garrison Michael David | EVP & President, Medical | Sell(S) | 479 | $197.28 | $94K |
| Apr 4, 2025 | Neal Shana Carol | EVP and Chief People Officer | Tax withholding(F) | 2K | — | $0 |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Coverage: Form 4 filings indexed 2021-01-04 → 2026-07-18. Earlier history is backfilling; this window widens as it deepens.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).